| DB ID | MyCo_3520 |
| Title | Clinical Relevance and Prognostic Value of Persistently Negative (1,3)-β-D-Glucan in Adults With Candidemia: A 5-year Experience in a Tertiary Hospital |
| Year | 2020 |
| PMID | 31680136 |
| Fungal Diseases involved | Candidemia |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | glabrata |
| Organism | Candida glabrata |
| Ethical Statement | This study was approved by the local ethics committee (CEIC-A1, Ref. 247/13). The need for inform consent was waived due to the non-interventional, retrospective characteristic of the study. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Prognostic |
| Biomolecule | Protein |
| Geographical Location | Spain |
| Cohort | We performed a retrospective study comprising all adults with candidemia diagnosed at our tertiary university hospital from January 2012 to December 2017, whose serum BDG had been assessed at least twice throughout the episode of candidemia. A protocol containing demographic, clinical and microbiological data was fulfilled for each episode until hospital discharge or death, according to definitions (see Supplementary Material). Blood cultures for the diagnosis of candidemia were always obtained from peripheral veins as were the serum samples for the BDG assays. Patients whose only positive blood cultures were drawn from the catheter were carefully excluded. During the period of study, 236 adults were diagnosed with candidemia, from which 148 (62.7%) had been evaluated with at least two serum BDG tests during the episode of infection. |
| Cohort No. | 236 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | Fungitell assay |
| Up Regulation Down Regulation | Negative |
| Sequence Data | None |
| External Link | None |
